Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

This research has been highlighted as a practice changing update by DynaMed Plus. It concludes that Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

Contributors : Heloisa H Milioli ; Neil PortmanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHere we characterise the response of models of ER-positive breast cancer to treatment with the small molecule MDM2 inhibitor NVP-CGM097, a dihydroisoquinolinone derivative currently evaluated in a phase I clinical trial. We show that NVP-CGM097 reduces tumour cell viability of in vitro and in vivo models of endocrine sensitive, endocrine resistant and palbociclib (CDK4/6 inhibitor) resistant p53 wildtype (p53wt) ER-positive breast cancer. NVP-CGM097 synergises with both fulvestrant and palbo...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
AbstractBreast cancer is a disease of aging, and the incidence of breast cancer is projected to increase dramatically as the global population ages. The majority of breast cancers that occur in older adults are hormone-receptor positive, human epidermal growth factor receptor-2 (HER2)-negative phenotypes, with favorable tumor biology; yet, because of underrepresentation in clinical trials, less evidence is available to guide the complex care for this population. Providing care for older patients with metastatic breast cancer, with coexisting medical conditions, increased risk of treatment toxicity, and frailty, remains a c...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
ns Verhaegh : Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel testing method was reported before that enables measurement of functional signal transduction pathway activity in individual cancer tissue samples, using mRNA levels of target genes of the respective pathway-specific transcription factor. Using this method, 130 primary breast cancer samples were analyzed fro...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Spironolactone is safe for the treatment of alopecia in breast cancer survivors taking endocrine therapy, new research shows.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news
CONCLUSIONS: Our study findings may aid in the development of behavioral interventions targeted to mitigate Black women breast cancer treatment disparities. We found modifiable factors (e.g. communication, satisfaction ratings) that support opportunities for clinicians to better address Black women's needs regarding adjuvant treatment options. The development of tailored interventions for newly diagnosed Black breast cancer patients on patient related factors in health care are warranted for Black women with lower educational levels. PMID: 32197898 [PubMed - as supplied by publisher]
Source: Journal of the National Medical Association - Category: General Medicine Tags: J Natl Med Assoc Source Type: research
Conditions:   Solid Tumor;   Advanced Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Hydroxychloroquine;   Drug: Faslodex;   Drug: Anastrazole;   Drug: Letrozole Sponsor:   Medical College of Wisconsin Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of lung cancer. Malignant tumors can proliferate indefinitely, and cell cycle regulation is abnormal which is one of the characteristics of malignant tumor. Cyclin D-dependent kinase (CDK) 4/6 inhibitor can prevent tumor cells from entering S phase through G1 phase and inhibit tumor proliferation. The CDK4/6 inhibitor has achieved good effect in hormone receptor positive breast cancer, and CDK4/6 inhibitor combined with endocrine therapy has become a standard treatment for this kind of patients. Cell ...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Contributors : Swaathi Jayaraman ; Xiaonan Hou ; Mary J Kuffel ; Vera J Suman ; Tanya L Hoskin ; Kathryn E Reinicke ; David G Monroe ; Krishna R Kalari ; Xiaojia Tang ; Megan A Zeldenrust ; Jingfei Cheng ; Elizabeth S Bruinsma ; Sarah A Buhrow ; Renee M McGovern ; Stephanie L Safgren ; Chad A Walden ; Jodi M Carter ; Joel M Reid ; James N Ingle ; Matthew M Ames ; John R Hawse ; Matthew P GoetzSeries Type : Expression profiling by arrayOrganism : Homo sapiensThe overarching goal of this study was to explore the antitumor activity of Z-endoxifen, a tamoxifen metabolite, with first-line endocrine therapies tamoxifen and letro...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)–targeted therapies. Individuals with TNBC experience higher rates of relapse and shorter overall survival compared to patients with receptor-positive breast cancer subtypes. Preclinical discoveries are needed to identify, develop, and advance new drug targets to improve outcomes for patients with TNBC. Here, we report that MYCN, an oncogene typically overexpressed in tumors of the nervous system or with neuroendocrine features, is heterogeneously exp...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Health | Hormones